Polar Capital’s Cytokinetics CYTK Stock Holding History

Polar Capital’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-500,000	Closed	-$11.8M	–	305
2020 Q2	$11.8M	Buy	+500,000	New	+$9.38M	0.1%	163

Other funds holding CYTK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Polar Capital's CYTK Position: Q3 2020 in Review

Polar Capital sold out of Cytokinetics (CYTK) in Q3 2020, closing a stake of 500,000 shares — an estimated $11.8M sold.

Polar Capital first reported a position in CYTK in Q2 2020 and held it in 1 quarter. The position peaked at $11.8M in Q2 2020. 181 funds tracked by Wall St. Rank hold CYTK as of Q3 2020.

Polar Capital reported no remaining Cytokinetics position as of Q3 2020 after selling out during the quarter.
Polar Capital sold 500,000 Cytokinetics shares in Q3 2020, an estimated $11.8M.
Polar Capital first reported a position in Cytokinetics in Q2 2020 and held it in 1 quarter.
Polar Capital's Cytokinetics position peaked at $11.8M in Q2 2020.
181 funds tracked by Wall St. Rank held Cytokinetics as of Q3 2020.

Based on Polar Capital's 13F filing for Q3 2020, filed 16 Nov 2020.